Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome
BACKGROUND: The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. PATIENTS AND METHODS: We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. RESULTS: With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. CONCLUSIONS: Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
Authors
- Giulio Mengozzi (ORCID: https://orcid.org/0000-0003-0431-8369)
- Luca Bertero (ORCID: https://orcid.org/0000-0001-9887-7668)
- Paola Cassoni (ORCID: https://orcid.org/0000-0003-1977-7410)
- Edoardo Pronello (ORCID: https://orcid.org/0000-0002-8680-0839)
- Gianluca Nocera (ORCID: https://orcid.org/0000-0002-8499-5257)
- Alberto Luigi Gallotti (ORCID: https://orcid.org/0000-0001-9698-7919)
- Laura Leoni (ORCID: https://orcid.org/0000-0003-2554-0620)
- Francesco Bruno (ORCID: https://orcid.org/0000-0001-8087-5293)
- Giovanni Morana (ORCID: https://orcid.org/0000-0001-8707-5969)
- Antonella Castellano (ORCID: https://orcid.org/0000-0002-4137-9016)
- Diego Garbossa (ORCID: https://orcid.org/0000-0002-2692-7133)
- Andrea Falini (ORCID: https://orcid.org/0000-0002-1461-8755)
- Marco Conti Nibali (ORCID: https://orcid.org/0000-0003-2611-5685)
- Alessia Andrea Ricci (ORCID: https://orcid.org/0000-0002-3989-0501)
- Alessia Pellerino (ORCID: https://orcid.org/0000-0003-3243-0059)
- Tommaso Sciortino (ORCID: https://orcid.org/0000-0001-6214-1253)
- Fabio Cofano (ORCID: https://orcid.org/0000-0002-5100-7478)
- Lorenzo Bello (ORCID: https://orcid.org/0000-0001-6797-7105)
- Riccardo Soffietti (ORCID: https://orcid.org/0000-0002-9204-7038)
- Roberta Rudà (ORCID: https://orcid.org/0000-0001-9134-1537)
- Federico Ponzetto (ORCID: https://orcid.org/0000-0002-9202-8013)
- Alessia Melis
- Lorenzo Gabriel Gay
- Francesca Scalvini (ORCID: https://orcid.org/0009-0002-0413-2572)
- Marco Rossi
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- Istituto Clinico Sant'Ambrogio (IT)
- IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT)
- IRCCS Ospedale San Raffaele (IT)
- Candiolo Cancer Institute (IT)
- University of Turin (IT)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1093/neuonc/noag282
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00